Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives

There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined equally either by Multicolor Flow Cytometry (MFC) or by Next Generation Sequencing (NGS) technologies. At present, mod...

Full description

Bibliographic Details
Main Authors: Alessandra Romano, Giuseppe Alberto Palumbo, Nunziatina Laura Parrinello, Concetta Conticello, Marina Martello, Carolina Terragna
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
flow cytometry
NGS
liquid biopsy
minimal residual disease
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00699/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00699/full

Similar Items